Monograph Details
|
|
Central Nervous System
> Seizure disorders
|
|
DILANTIN INFATABS |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Hydantoin. |
| Generic Name |
|
Phenytoin 50mg; chewable tabs. |
| Also |
• DILANTIN
• DILANTIN SUSPENSION
|
| Indications |
|
Tonic-clonic, psychomotor and neurosurgically induced seizures. |
| Children |
|
Initially 5mg/kg per day in 2–3 equally divided doses. Increase weekly if needed. Usual maintenance: 4–8mg/kg per day; max 300mg daily. |
| Adults |
|
Initially: 100mg 3 times daily. Increase weekly if needed; max 200mg 3 times daily. Once-a-day dosing only with ext-rel caps for patients controlled on 300mg daily. |
| Precautions |
|
Diabetes. Impaired liver function. Change dose gradually. Discontinue if rash develops. Monitor serum levels. Use proper dental hygiene. Hormonal contraception. Porphyria. Elderly. Debilitated. Pregnancy. Nursing mothers: not recommended. |
| Interactions |
|
Potentiated by acute alcohol ingestion, amiodarone, benzodiazepines (eg, diazepam), chloramphenicol, dicumarol, disulfiram, estrogens, fluoxetine, halothane, H2 blockers, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinamides (eg, ethosuximide), sulfonamides, tolbutamide, trazodone, others. Antagonized by chronic alcohol ingestion, carbamazepine, reserpine, others. Antagonizes tricyclic antidepressants, oral anticoagulants, oral contraceptives, estrogens, corticosteroids, doxycycline, digitoxin, furosemide, theophylline, rifampin, quinidine, vitamins D and K, others. Variable effects with phenobarbital, valproic acid, divalproex, others. Absorption decreased by calcium, antacids. |
| Adverse Reactions |
|
Nystagmus, ataxia, slurred speech, decreased coordination, dizziness, GI disturbances, gingival hyperplasia, osteomalacia, blood dyscrasias, lymphadenopathy, hepatic disease, rash, hyperglycemia, SLE, hypertrichosis. |
| How Supplied |
Caps, Tabs—100
Susp—8oz |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
